Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registryTorbjörn Tomson, Maria Paola Canevini, Anne Sabers et al.|The Lancet Neurology|2018Cited by 537
Initial high-efficacy disease-modifying therapy in multiple sclerosisMathias Due Buron, Melinda Magyari, Thor Ameri Chalmer et al.|Neurology|2020Cited by 160
Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple SclerosisIzanne Roos, Vincent Van Pesch, Stella Hughes et al.|JAMA Neurology|2023Cited by 62